Merck: Sac-TMT Cuts Risk of Death 32% in Advanced Endometrial Cancer
Key Facts
Merck said on October 26, 2026, that its investigational drug sacituzumab tirumotecan, known as sac-TMT, reduced the risk of death 32% among patients with advanced or recurrent endometrial cancer in the Phase 3 TROPiCS-005 trial. Median overall survival was 19.0 months with the drug, compared with 12.1 months with physician’s choice of chemotherapy, after a median follow-up of 14.0 months. The prespecified interim analysis was conducted in patients whose disease had progressed after platinum-based chemotherapy and anti-PD-1 or PD-L1 immunotherapy. The company said the trial achieved statistically significant and clinically meaningful improvement in both primary endpoints, overall survival and progression-free survival. The results target a group of patients with limited treatment options after their disease progresses following prior therapies.
For the other primary endpoint, the risk of disease progression or death fell 41% with sac-TMT compared with chemotherapy, and median progression-free survival was 7.2 months versus 3.9 months. The hazard ratio was 0.59, with a 95% confidence interval of 0.50 to 0.70, and Merck said the result was statistically significant. The trial included 776 patients, randomly assigned to the drug or physician’s choice of treatment, consisting of doxorubicin or paclitaxel. The study was global and multicenter, and was open-label and controlled with an active treatment. Merck said TROPiCS-005 is the first global Phase 3 trial and the first trial of a TROP2-directed antibody-drug conjugate to show significant improvement in both measures in this patient group.
Response measures also favored the drug: the objective response rate was 35.1% with sac-TMT, compared with 17.3% with physician’s choice of treatment. Median duration of response was 11.1 months among patients receiving the drug, compared with 6.9 months in the chemotherapy group. By contrast, treatment-related adverse events of Grade 3 or higher were more common with sac-TMT, at 54.4% versus 41.4%. Treatment discontinuation rates were 3.1% in the drug group and 4.9% in the comparison group. Merck said health-related quality of life was maintained over time and the safety profile revealed no new signals; deaths attributed to treatment-related events were 0.8% in each arm.
The results were presented in a presidential session at the 2026 European Society for Medical Oncology Congress and published simultaneously in The Lancet, according to Merck. The global readout follows early data from a Phase 1/2 study in China, where the 4 mg/kg dose group recorded an objective response rate of 36.9% and median progression-free survival of 5.6 months. Fierce Pharma quoted a Merck official as saying the global results were largely consistent with the China data. By disease stage, five-year relative survival rates vary: 94.9% for localized disease and 19.9% for disease that has spread to distant sites, according to the National Cancer Institute. The institute’s data indicate that 67% of cases are diagnosed locally, while 11% are diagnosed after spreading to distant sites.
The company is preparing for the regulatory process after the FDA accepted the sac-TMT application for priority review to treat adults with the disease following platinum-containing treatment and a PD-1 or PD-L1 inhibitor, alone or in combination. The agency set June 15, 2027, as the target decision date. Merck said it will discuss the data with global regulatory authorities. The TROPiCS program currently includes 18 ongoing global Phase 3 trials across multiple tumor types, including 10 trials in gynecologic cancers. These include TROPiCS-033, which is studying the drug as first-line treatment for endometrial cancer in patients with mismatch repair-proficient tumors. Merck estimated that about 68,270 patients will be diagnosed with endometrial cancer in the United States during 2026, with about 14,450 expected deaths from the disease.
Principal investigator Bhavana Pothuri said the study results warrant a reassessment of clinical guidelines for endometrial cancer to include sac-TMT, in research commentary published by NYU Langone. Dean Li, president of Merck Research Laboratories, described the situation for patients whose disease progresses after platinum-based treatment and a PD-1 inhibitor, saying they "face median survival of less than a year with current treatments." He added that an increase in survival of about seven months represents important progress. Merck said the investigational drug, which it is developing with Kelun-Biotech, targets the TROP2 protein. Merck shares closed at $145.27 on October 23, 2026, according to EL7 data. Pothuri’s comment remains a research opinion, while the regulatory path will be determined by the target decision in June 2027.